Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia
Launched by UNIVERSITY HOSPITAL, ESSEN · Jul 8, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain factors related to low oxygen levels (called hypoxic induced factors) might affect patients with hereditary hemorrhagic telangiectasia (HHT). HHT is a genetic disorder that causes abnormal blood vessel formation, which can lead to bleeding and other health issues. The researchers want to understand if these low oxygen factors could play a role in the development of new blood vessels in people with HHT.
To participate in this study, individuals must be at least 17 years old and have a confirmed diagnosis of HHT, either through genetic testing or by meeting specific clinical criteria. Participants will have the opportunity to help researchers learn more about HHT and its mechanisms, which could lead to better treatments in the future. The trial is currently recruiting, and anyone interested should discuss their eligibility with their healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed HHT (genetic testing and/ or fulfill at least 3 Curacao Criteria)
- • older than 17 years
- • ability to consent
- Exclusion Criteria:
- • if inclusion Criteria are not met
About University Hospital, Essen
The University Hospital Essen is a leading academic medical center dedicated to advancing healthcare through innovative research and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical disciplines to facilitate cutting-edge studies aimed at improving patient outcomes. With a commitment to scientific excellence and patient safety, the University Hospital Essen collaborates with a network of researchers and healthcare professionals to explore new therapies and treatment modalities, contributing significantly to the field of medicine and enhancing the overall quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Essen, Nrw, Germany
Patients applied
Trial Officials
Freya Droege, MD
Principal Investigator
University hospital Essen Otorhinolaryngology, Hufelandstr. 55, 45147 Essen, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials